|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Arisaph Pharmaceuticals Inc., of Boston, completed the second closing of a $16 million financing round, raising an additional $8 million in a private equity investment from Cranbury, N.J.-based Kos Pharmaceuticals Inc. and 2004 Oikos Investment Partners LP. The financing was triggered by the completion of certain development milestone in Arisaph's DPP-IV inhibitor, ARI 2243, and its ultra-smart cancer program. Arisaph intends to use the proceeds to advance ARI 2243 into clinical testing and to select lead candidates of its ultra smart prodrugs for cancer.
o BioCryst Pharmaceuticals Inc., of Birmingham, Ala., saw its shares drop 15 percent Wednesday after ...